Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly/BI Report Success For Oral Diabetes Drug, Adjust Alliance

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Eli Lilly and Boehringer Ingelheim announced positive top-line data for a quartet of pivotal trials of their SGLT-2 candidate empagliflozin, while Lilly now will be going it alone on LY2605541, a long-acting insulin.

You may also be interested in...



Bristol Signals Dapaglifozin’s Back On Track, Plans FDA Resubmission

Bristol suggests FDA has had a change of heart on the evolving filing package for diabetes drug dapagliflozin. Meanwhile, the company sees no additional U.S. regulatory hurdles ahead for the eagerly awaited, novel oral anticoagulant Eliquis.

Boehringer’s Smith Discusses The Challenges Of Diabetes At ADA

Relatively new to the diabetes space, Boehringer Ingelheim is trying to rapidly distinguish itself in a crowded field with four products each addressing a different patient need.

New Long-Acting Insulin Offerings Could Derail Lantus Franchise

Companies presented data at ADA that could give patients options other than Lantus, but Sanofi is fighting back with a strategy to retain them.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS005233

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel